MedAxiom Announces Industry Partnership With Cell>Point
MedAxiom Announces Industry Partnership With Cell>Point with Video Cell>Point, improving lives through imaging and targeted therapy. Partner News…
Read
Cell>Point plans to expedite research program on 99mTc-EC-Amifostine and 177Lu-EC- Amifostine as a potentially effective theranostic technology for COVID-19
CENTENNIAL, Colorado, March 24, 2020 – Cell>Point announced today its plans to move forward with its research program…
Read
Cell>Point Expanding Theranostic Clinical Research to Include Platinum and 177Lu Targeted Therapy to Compliment Oncardia Imaging Platform
CENTENNIAL, Colorado, January 21, 2020 – Cell>Point announced today, based on its sponsored chelator and therapeutic research conducted…
Read
Cell>Point announced today that it plans to begin patient recruitment for its Phase 2b cardiovascular imaging study in patients suffering from coronary artery disease using the new one-vial Oncardia
CENTENNIAL, Colorado, May 17, 2019 – Cell>Point announced today that it plans to begin patient recruitment for its…
Read
CellPoint, L.L.C. announced today that it has entered into automated production agreement with KP Pharmaceutical Technologies for lead molecular imaging agent Oncardia®
CENTENNIAL, Colorado, September 18, 2018 – CellPoint announced today that it has entered into an automated production agreement with…
Read
Noninferiority of 99mTc Ethylenedicystein Glucosamine (Oncarida) as a Alternative Analogue to 18F Flurodeoxyglucose in the Detection and Staging of Non Small Cell Lung Cancer
Published March 19, 2018, Hindawi Contrast Media & Molecular Imaging https://celltheranostics.com/wp-content/uploads/2019/11/Noninferiority-of-99mTc-Ethylenedicystein.pdf
Read
Targeting the Hexosamine Biosynthetic Pathway and O-linked N-acetylglucosamine cycling for therapeutic and imaging capabilities in diffuse large B-cell lymphoma
Oncotarget, Advance Publications 2016 https://celltheranostics.com/wp-content/uploads/2019/11/12413-186535-1-PB-2016-EC-G-Paper.pdf
Read
Cell>Point enters into license agreement with Vyripharm Biopharmaceuticals for the use of Cell>Point’s In-Situ Hydrogel, N4 Technology and Oligosaccharide (Dual Agent) Technology
CENTENNIAL, Colo., August 24, 2016 – Cell>Point today announced it has entered into license agreements with Vyripharm Biopharmaceuticals for…
Read
Cell>Point Executes China License with United Eastern Pharmaceutical for Oncardia® for Cancer and Heart Disease Diagnostic Imaging
CENTENNIAL, Colo., June 16, 2016 – Cell>Point today announced that it has entered into an exclusive license agreement for…
Read
Cell>Point Announces Postive Results from 99mTc-Oncardia® (EC- G) trial at the Unviersity of Chicago Medical Center to image and montior therapy for Head and Neck Cancer.
CENTENNIAL, Colo., January 15, 2015 – Cell>Point announced today positive results following conclusion of a Head and Neck…
Read
